Company news

Aligos Therapeutics, Inc. news in 2023

Aligos Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Aligos Therapeutics Presents Positive Clinical Data at Hep-DART 2023 from Phase 1 Studies in HBV (ALG-000184) and NASH (ALG-055009)

December 6, 2023

Aligos Therapeutics Presents Clinical and Nonclinical Data at the AASLD Liver Meeting® 2023 Demonstrating that ALG-055009 has a Favorable Risk-Benefit Profile

November 12, 2023

Aligos Therapeutics Presents Positive Data at the AASLD Liver Meeting® 2023 Demonstrating that Treatment with ALG-000184 (CAM-E) Results in Significant Multi-log Reductions in Hepatitis B Antigens (HBsAg, HBcrAg and HBeAg)

November 9, 2023

Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results

November 1, 2023

Aligos Therapeutics to Announce 3rd Quarter Results on November 2, 2023

October 25, 2023

Aligos Therapeutics Announces $92 Million Private Placement Financing

October 22, 2023

Aligos Therapeutics Announces Award of an $8.5 Million NIAID Contract to Advance Development of Best-In-Class Pan-Coronavirus Protease Inhibitor, ALG-097558

October 2, 2023

Aligos Therapeutics Announces IND Clearance for NASH lead, ALG-055009

September 20, 2023

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results

August 2, 2023

Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023

July 26, 2023

Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009

July 18, 2023

Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

June 20, 2023

Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023

June 6, 2023

Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference

May 23, 2023

Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases

May 11, 2023

Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results

May 3, 2023

Aligos Therapeutics to Announce First Quarter Results on May 4, 2023

April 26, 2023

Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023

April 10, 2023

Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference

March 28, 2023

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

March 8, 2023

Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

February 27, 2023

Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024

February 7, 2023

Decks in 2023